PHYSICIAN AWARENESS AND INDICATIONS OF 5-ALPHA REDUCTASE INHIBITOR USE FOR BENIGN PROSTATIC HYPERPLASIA IN THE PRIMARY CARE SETTING

被引：0
|
作者：
Loloi, J. [1 ]
Alicea, D. [2 ]
Babar, M. [2 ]
Shah, J. [2 ]
Azhar, U. [2 ]
Labagnara, K. [2 ]
Salam, A. [2 ]
Tang, K. [2 ]
Robles, J. [1 ]
Maria, P. [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF SEXUAL MEDICINE | 2024年 / 21卷
关键词：
D O I：
10.1093/jsxmed/qdae167.213
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
218
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ASSESSING PRIMARY CARE PHYSICIANS AWARENESS OF 5-ALPHA REDUCTASE INHIBITORS FOR MEN WITH BENIGN PROSTATIC HYPERPLASIA
    Babar, M.
    Loloi, J.
    Azhar, U.
    Labagnara, K.
    Salami, A.
    Tang, K.
    Robles, J.
    Maria, P.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [2] The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
    Kim, Eric H.
    Brockman, John A.
    Andriole, Gerald L.
    ASIAN JOURNAL OF UROLOGY, 2018, 5 (01) : 28 - 32
  • [3] Risk of Gynecomastia with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Nickel, J. Curtis
    Fang, Shona
    Jick, Susan S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 531 - 532
  • [4] CELLULAR MECHANISMS OF 5-ALPHA REDUCTASE INHIBITOR TREATMENT RESISTANCE IN BENIGN PROSTATIC HYPERPLASIA
    Joseph, Diya Binoy
    Henry, Gervaise
    Malewska, Alicia
    Reese, Jeffrey
    Mauck, Ryan
    Gahan, Jeffrey
    Hutchinson, Ryan
    Mohler, James
    Roehrborn, Claus
    Strand, Douglas
    JOURNAL OF UROLOGY, 2021, 206 : E201 - E201
  • [5] Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
    Kim, Won
    Jung, Jae Hung
    Kang, Tae Wook
    Song, Jae Mann
    Chung, Hyun Chul
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (01) : 52 - 56
  • [6] Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance
    Jin, Renjie
    Forbes, Connor M.
    Miller, Nicole L.
    Lafin, John
    Strand, Douglas W.
    Case, Thomas
    Cates, Justin M.
    Liu, Qi
    Ramirez-Solano, Marisol
    Mohler, James L.
    Matusik, Robert J.
    PROSTATE, 2024, 84 (05): : 441 - 459
  • [7] Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Fang, Shona C.
    Nickel, J. Curtis
    Jick, Susan S.
    CLINICAL EPIDEMIOLOGY, 2017, 9 : 83 - 91
  • [8] The Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures
    Lim, Sian Yik
    Laengvejkal, Pavis
    Panikkath, Ragesh
    Nugent, Kenneth
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 347 (06): : 463 - 471
  • [9] Risk of Erectile Dysfunction Associated with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Persson, Rebecca
    Nickel, J. Curtis
    Jick, Susan S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 465 - 466
  • [10] Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha- reductase
    Polat Ö.
    Özbey I.
    Gül O.
    Demirel A.
    Bayraktar Y.
    International Urology and Nephrology, 1997, 29 (3) : 323 - 330
12345